Objectives: In Neisseria gonorrhoeae, the mosaic structure of penicillin-binding protein 2 (PBP 2), composed of fragments of PBP 2 from Neisseria cinerea and Neisseria perflava, was significantly associated with decreased susceptibility to cephalosporins, particularly oral cephalosporins. The aim of this study was to determine the affinity of mosaic PBP 2 for cephalosporins in N. gonorrhoeae.
Introduction
Penicillins and tetracyclines were commonly used for the treatment of gonococcal infections until the emergence of penicillinand tetracycline-resistant strains of Neisseria gonorrhoeae. Fluoroquinolones and broad-spectrum cephalosporins have since been used as primary therapies for uncomplicated gonococcal infections. 1, 2 Since the mid-1990s in Japan, however, the failure of fluoroquinolone treatment, related to the development of fluoroquinolone resistance in N. gonorrhoeae strains, has been reported. 3 Therefore, cephalosporins are now used as the primary treatment for gonococcal infections, although certain clinical isolates of N. gonorrhoeae have been found to be less susceptible to oral cephalosporins, including cefixime, in Japan. 4 -6 Penicillin-binding proteins (PBPs) are membrane-bound enzymes that catalyse the final steps in cell wall biosynthesis and are the targets of the b-lactam antibiotics. 7 -13 Cephalosporins prevent cell wall synthesis in N. gonorrhoeae by binding to PBPs on the cytoplasmic membrane. Analyses of membrane fractions of N. gonorrhoeae labelled with radioactive penicillin indicate that this bacterial species possesses three PBPs: PBP 1, 2 and 3.
14, 15 Analysis of the complete genomic sequence of N. gonorrhoeae indicates the existence of a fourth PBP, PBP 4. 16 Inhibition of PBP 1 or 2 may result in the inhibition of bacterial growth, whereas PBPs 3 and 4 may not be involved in cell viability. 13, 17 PBPs 1 and 2 are major targets of b-lactam antibiotics used against N. gonorrhoeae. Many studies of the molecular mechanisms underlying the resistance of N. gonorrhoeae to b-lactam antibiotics have been reported. penA causes the insertion of a single amino acid into PBP 2, reducing penicillin binding. 18 Recently, ponA1 and another resistance locus, termed penC, were shown to be involved in penicillin resistance.
19 ponA1 encodes PBP 1, containing a single amino acid alteration of Leu-421!Pro, which decreases the rate of acylation with b-lactam antibiotics. penC is required to transform an intermediate-level penicillin-resistant strain possessing ponA1 into a high-level resistance strain. In addition, the mechanisms for chromosomally mediated resistance of N. gonorrhoeae to penicillin G involve penB and mtr mutations. 20 The penB mutation, which is linked to the porin gene, reduces porin permeability to hydrophilic antibiotics and plays an important role in the development of resistance to penicillin G, cephalosporins and tetracycline. mtr increases expression of the MtrCDE efflux pump and modulates gonococcal resistance to hydrophobic agents. 21 However, these mechanisms appear not to affect the susceptibilities of N. gonorrhoeae strains to cephalosporins so much as to threaten the efficacy of currently recommended cephalosporin regimens for the treatment of gonorrhoea. Recently, the penA gene of clinical isolates of N. gonorrhoeae with decreased susceptibility to oral cephalosporins in Japan was reported to have a mosaic structure. 22 We also identified a mosaic PBP 2 in clinical isolates of N. gonorrhoeae, composed of fragments of PBP 2 from Neisseria cinerea and Neisseria perflava. 23 This mosaic alteration of PBP 2 showed significant association with decreased susceptibility to cephalosporins. One of the assumed mechanisms underlying the decreased susceptibility to cephalosporins is the reduced affinity of the mosaic PBP 2 for these agents. However, no study on the affinity of mosaic PBP 2 for cephalosporins has yet been reported.
In this study, two types of N. gonorrhoeae PBP 2, mosaic and non-mosaic, were expressed in insect cells by means of a baculovirus expression vector system, and a large quantity of recombinant PBP 2 was purified. Bindings of fluorescent penicillin to PBP 2 were characterized by the Scatchard plot analysis. PBP 2 competition assays with fluorescent penicillin were performed to determine the affinity of each of the recombinant PBP 2s for b-lactam antibiotics, including penicillin V, cefdinir, cefixime and ceftriaxone.
Materials and methods

N. gonorrhoeae strains
This study used the type strain of N. gonorrhoeae (ATCC 19424) and two clinical strains of N. gonorrhoeae (GU01-29 and GU01-89) isolated from men with gonorrhoea at Gifu University Hospital or its affiliated hospital in central Japan. These strains were included in our previous study, in which susceptibilities to penicillin, cephalosporins and PBP 2 isoforms were analysed. 23 MICs of b-lactam antibiotics for each strain were previously determined by the agar dilution method. 5 
Construction of recombinant transfer vectors
DNAs were extracted from the strains by the phenol-chloroform method. 24 Amplification of the penA gene was performed by PCR with primers penA-F2 (5 0 -GAATTCTTGATTAAAAGCGAATA TAAGCCC-3 0 ) (Operon Biotechnologies, Huntsville, AL, USA) and penA-R3 (5 0 -GCGGCCGCTTAAGACGGTGTTTTGACGGCT-3 0 ) (Operon Biotechnologies). PCR products were cloned into the cloning vector pCR2.1 (Invitrogen, San Diego, CA, USA), to generate penA/pCR2.1 in TOP10 (Invitrogen). penA/pCR2.1 was digested with EcoRI and NotI, and the DNA fragments were ligated to transfer vector pAcHLT-A (BD Biosciences, San Jose, CA, USA), which was digested with EcoRI and NotI, to produce penA/pAcHLT-A in TOP10. The transfer vector pAcHLT-A encoded an N-terminal 6ÂHis tag and an extended multiple cloning site.
Generation of recombinant baculoviruses and expression of PBP 2
Sf9 cells (Invitrogen) derived from an insect cell line were co-transfected with linearized baculovirus DNA (BD Biosciences) and penA/pAcHLT-A by the lipofectin-mediated method. 25 The cells were incubated at 26.58C in Sf-900II medium (GIBCO), and recombinant baculoviruses were generated. 26 Each recombinant virus was plaque-purified three times. 26 In addition to the Sf9 cells, we used an insect cell line from Trichoplusia ni, BTL-Tn 5B1-4 (Tn5) (Invitrogen), for large-scale expression. Tn5 cells were infected with recombinant baculoviruses at a multiplicity of infection of 10 and were incubated in Excell 405 medium (JRH Biosciences, Lenexa, KS, USA) for 3 days at 26.58C until an extensive cytopathic effect was observed.
Purification of recombinant PBP 2
Three types of recombinant PBP 2 were purified with a 6ÂHis expression and purification kit (BD Biosciences). Infected 9.0Â10 7 Tn5 cells were harvested and centrifuged at 1000Âg for 15 min. The cell pellet was resuspended in ice-cold insect cell lysis buffer (10 mM Tris, pH 7.5, 130 mM NaCl, 2% Triton X-100, 10 mM NaF, 10 mM NaPi, 10 mM NaPPi) containing a protease inhibitor cocktail (16 mg/L benzamidine HCl, 10 mg/L phenanthroline, 10 mg/L aprotinin, 10 mg/L leupeptin, 10 mg/L pepstatin A and 1 mM PMSF). Five millilitres of cell lysis buffer was used, and the lysed cells were maintained on ice for 45 min. This was followed by filtration through a 0.22 mm filter to obtain a clear lysate containing recombinant 6ÂHis PBP 2. The lysate was added at a one-tenth volume to Ni-NTA agarose and incubated at 48C for 1 h on a rocking platform. The bead slurry was washed four times with 10 bead volumes of 6ÂHis wash buffer (50 mM Na-phosphate, 300 mM NaCl, 30 mM imidazole, 10% glycerol, pH 8.0). Recombinant 6ÂHis PBP 2 was eluted $0.9 mg with 6ÂHis elution buffer (50 mM Na-phosphate, 300 mM NaCl, 300 mM imidazole, 10% glycerol, pH 6.0). Eluted proteins were confirmed to be recombinant 6ÂHis PBP 2 by SDS-PAGE and Pro-Q w Sapphire 532 Oligohistidine Gel Stain (Molecular Probes, Eugene, OR, USA).
Fluorescent penicillin binding
Each of the recombinant PBP 2s (2.5 mg) from N. gonorrhoeae (ATCC 19424) and from the two clinical strains of N. gonorrhoeae (GU01-29 and GU01-89) was incubated with BOCILLIN TM FL penicillin (Molecular Probes) in the presence or the absence of a 1000-fold excess of unlabelled penicillin V (Sigma-Aldrich) for 10 min at 308C. PBP 2s were then solubilized with sarcosyl and resolved by SDS-PAGE; then, the gels were analysed by the luminescent image analyser LAS-3000 (FUJIFILM, Tokyo, Japan). These experiments were performed in duplicate.
PBP 2 competition assay
The affinity of the recombinant PBP 2 for penicillin V, cefdinir, cefixime and ceftriaxone was measured by a modified competition assay. 27 In brief, each PBP 2 (2.5 mg) was incubated with BOCILLIN TM FL penicillin (100 pmol) in the presence of increasing concentrations of b-lactam antibiotics (1-10 5 pmol) for 10 min at 308C. Complexes of antibiotics and PBP 2s were then solubilized with sarcosyl, and labelled PBP 2s were resolved by SDS-PAGE; then, the gels were analysed by a luminescent image analyser LAS-3000. PBP 2 competition assays were performed in triplicate. IC 50 was defined as the concentration of unlabelled antibiotic that decreased binding of BOCILLIN TM FL penicillin to a PBP 2 by 50%.
Results
Expression and purification of PBP 2
Proteins of 64 kDa molecular weight, consistent with that of PBP 2s, were expressed in Tn5 cells infected with baculovirus with the penA gene amplified from ATCC 19424, GU01-29 and GU01-89. The proteins were purified from insect cell lysates by the 6ÂHis tag. Eluted proteins were confirmed to be recombinant 6ÂHis PBP 2 by SDS-PAGE and Pro-Q w Sapphire 532 Oligohistidine Gel Stain. .27 pmol were required for ceftriaxone. The affinity of mosaic-structure recombinant PBP 2 from GU01-89 for cefdinir or cefixime was lower than that of the non-mosaic-structure recombinant PBP 2s from ATCC 19424 and GU01-29. The affinity of the mosaicstructure recombinant PBP 2 for ceftriaxone was not changed, compared with that of the non-mosaic-structure recombinant PBP 2s from ATCC 19424 and GU01-29.
Discussion
In our previous study, we identified mosaic PBP 2 in clinical isolates of N. gonorrhoeae that was composed of fragments from PBP 2 of N. cinerea and N. perflava. 23 The interspecies horizontal exchange of the penA genes or gene parts has been observed among penicillin-resistant strains of N. gonorrhoeae, 28, 29 Neisseria lactamica, 30 Neisseria meningitidis 31 and Neisseria mucosa. 30 Commensal species such as Neisseria flavescens and N. cinerea, which are intrinsically more resistant to penicillin than pathogenic species, have been identified as the donors in these interspecies exchanges. 29, 32 In the present study, this mosaic PBP 2 was significantly associated with decreased susceptibility to oral cephalosporins. Alteration in the affinity of PBPs for oral cephalosporins may be associated with the acquisition of resistance to these agents. However, no studies have appeared on the altered affinity of mosaic PBP 2 for cephalosporins. One reason may be that it is difficult to culture large amounts of N. gonorrhoeae in liquid broth and to obtain large quantities of a membrane fraction, including PBPs. In the present study, we expressed PBP 2 in insect cells with recombinant baculovirus and purified non-mosaic-structure recombinant PBP 2s and mosaic-structure recombinant PBP 2. This approach allowed us to determine the affinity of mosaic-structure recombinant PBP 2 for cephalosporins.
In the present study, the K d values showed that the affinity of BOCILLIN TM FL penicillin for mosaic-structure recombinant PBP 2 was lower than that of non-mosaic-structure recombinant PBP 2s from ATCC 19424 and GU01-29. Furthermore, mosaicstructure recombinant PBP 2 from GU01-89 exhibited IC 50 values 20 times higher for cefdinir and 3 times higher for cefixime than that of non-mosaic-structure recombinant PBP 2 from ATCC 19424. In spite of the decreased affinity of BOCILLIN TM FL penicillin for mosaic PBP 2, the affinity of cefdinir and cefixime for this type of PBP 2 was decreased in the PBP 2 competition assay. These results indicated that the extent of the decrease in the affinity of mosaic PBP 2 for cefdinir and cefixime could be greater than that for BOCILLIN TM FL penicillin. Therefore, the affinity of mosaic-structure recombinant PBP 2 from GU01-89 for oral cephalosporins was lower than that of non-mosaic-structure recombinant PBP 2s.
In a previous study, we sequenced the penA gene in 70 clinical isolates of N. gonorrhoeae and found this type of mosaic PBP 2 in 47 isolates. 23 All of the isolates with mosaic PBP 2, cephalosporin-resistant and -susceptible types based on the presence or the absence of mosaic PBP 2.
It should be noted that ceftriaxone was more active against ATCC 19424 with penicillin-susceptible non-mosaic-structure recombinant PBP 2 than cefdinir or cefixime and showed a lower IC 50 value for the non-mosaic-structure recombinant PBP 2 than cefdinir or cefixime. The affinity of non-mosaic-structure recombinant PBP 2 with Asp-345a and the affinity of mosaicstructure recombinant PBP 2 for ceftriaxone were not changed, compared with non-mosaic-structure recombinant PBP 2 from ATCC 19424. The results of our previous study showed that the ceftriaxone MICs for isolates with mosaic PBP 2, ranging from 0.015 to 0.25 mg/L, were significantly greater than those for isolates with non-mosaic PBP 2, which ranged from 0.004 to 0.125 mg/L. However, the distribution of the former MICs overlapped that of the latter MICs, and some isolates with mosaic PBP 2 showed lower ceftriaxone MICs than those with nonmosaic PBP 2. The findings of our present study, together with those of our previous study, indicate that the mosaic form decreases the affinity of PBP 2 for cephalosporins, contributing to decreased susceptibility to these antibiotics. However, the same IC 50 value of mosaic-structure recombinant PBP 2 for ceftriaxone was observed when compared with that of non-mosaic-structure recombinant PBP 2 with Asp-345a. The isolates with mosaic PBP 2 and non-mosaic PBP 2 exhibited wide ranges of ceftriaxone MICs that overlapped with each other. In clinical isolates of N. gonorrhoeae, the susceptibilities of cephalosporins, particularly ceftriaxone, appeared to be determined not only by alterations in PBP 2 but also by other mechanisms. 19 -21,33 For most b-lactam antibiotics, PBP 2 is the potential target for killing cells of N. gonorrhoeae. However, several antibiotics exhibit high levels of binding to PBP 1 as well as PBP 2 in both susceptible and resistant strains. Therefore, the findings of the present study also suggest that the acquisition of high levels of resistance to cephalosporins in clinical isolates may be accompanied by an additional change in PBP 1 affinity and/or other resistance mechanisms. We suggest that the decreased affinity of mosaic-structure recombinant PBP 2 for cephalosporins may contribute to decreased susceptibility to these antibiotics. The present study was limited by the fact that other PBPs were not analysed for affinity for cephalosporins and by the fact that the quantities of PBPs, including mosaic PBP 2, expressed in the cells were not assessed because recombinant PBP 2s were analysed instead of membrane fractions of N. gonorrhoeae. We also did not analyse porin permeability or efflux pump expression in this study. Other mechanisms may be involved in the decreased susceptibility to these agents. Nevertheless, this is the first study to analyse the affinity of mosaic-structure recombinant PBP 2 to cephalosporins. The results should prove useful for elucidating the mechanisms of cephalosporin resistance in clinical strains of N. gonorrhoeae.
